Atogepant and sumatriptan: no clinically relevant drug-drug interactions in a randomized, open-label, crossover trial

Aim: To evaluate pharmacokinetic interactions of atogepant with sumatriptan, an open-label, randomized, crossover study was conducted. Patients & methods: Thirty healthy adults received atogepant 60 mg, sumatriptan 100 mg, or coadministered drugs. Primary end point was geometric mean ratios (GMRs) and 90% CIs of interventions for area under the plasma concentration-time curve from time 0 to t (AUC_0-t) or infinity (AUC_0-∞) and peak plasma concentration (C_max). Results: Atogepant GMRs for AUC_0-t and AUC_0-∞ versus with sumatriptan were within 90% CI 0.80-1.25, indicating no interaction; atogepant C_max was reduced by 22% (GMR: 0.78; 90% CI: 0.69-0.89) with sumatriptan. Sumatriptan GMRs for AUC_0-t, AUC_0-∞ and C_max versus with atogepant were within 90% CI 0.80-1.25. Conclusion: Atogepant with sumatriptan had no clinically relevant pharmacokinetic interactions.